•
Sep 30, 2024

XpresSpa Q3 2024 Earnings Report

XWELL's third quarter performance in 2024 was marked by growth and productivity initiatives.

Key Takeaways

XWELL, Inc. reported a revenue of $8.4 million for the third quarter of 2024, compared to $7.5 million for the 2023 third quarter. The operating loss was approximately $4.8 million, compared with an operating loss of approximately $12.1 million for the 2023 third quarter. Net loss attributable to XWELL was approximately $4.8 million, compared to approximately $11.5 million for the 2023 third quarter.

Total revenue for the third quarter ended September 30, 2024, was $8.4 million, compared to $7.5 million for the 2023 third quarter.

Revenue for the 2024 third quarter primarily consisted of approximately $4.9 million from XpresSpa locations and Treat locations and approximately $3.1 million from XpresTest, which includes XWELL’s bio-surveillance partnership and its HyperPointe business.

The operating loss was approximately $4.8 million, compared with an operating loss of approximately $12.1 million for the 2023 third quarter.

As of September 30, 2024, the Company had approximately $4.4 million of cash and cash equivalents and approximately $11.7 million in marketable securities.

Total Revenue
$8.42M
Previous year: $7.47M
+12.8%
EPS
-$0.99
Previous year: -$2.38
-58.4%
Gross Profit
$1.8M
Previous year: $1.1M
+63.7%
Cash and Equivalents
$4.4M
Previous year: $4.8M
-8.3%
Free Cash Flow
-$3.83M
Previous year: -$4.66M
-17.9%
Total Assets
$19.5M
Previous year: $42.9M
-54.6%

XpresSpa

XpresSpa

Forward Guidance

XWELL believes it's well-positioned for a strong 2025 and remains confident that its consistent strategy execution will benefit its customers, partners, employees, and shareholders.